---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-116477"
form_type: "8-K"
ticker: "RZLT"
cik: "0001509261"
company_name: "Rezolute, Inc."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T01:10:27.026873+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Rezolute Q1 FY2023 net loss $9.8M; cash $154.3M; RZ358/402 advance

## Summary
- Cash and equivalents $154.3M as of Sep 30, 2022; net loss $9.8M vs $7.8M YoY.
- R&D expenses $7.7M (up 33% YoY); G&A $2.5M (up 32% YoY) on higher clinical and stock-based costs.
- RZ358 Phase 2b showed ~75% reduction in hypoglycemia events; regulatory discussions underway for Phase 3.
- RZ402 Phase 1b MAD data supports once-daily dosing; Phase 2 proof-of-concept study expected by end-2022.
- Closed $130M financing post-quarter to advance both molecules into next clinical stages.

## SEC filing metadata
- accession: 0001104659-22-116477
- form_type: 8-K
- ticker: RZLT
- cik: 0001509261
- company_name: Rezolute, Inc.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509261/000110465922116477/0001104659-22-116477-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509261/000110465922116477/tm2230110d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-116477
- JSON: https://secwatch.observer/filing/0001104659-22-116477.json
- Plain text: https://secwatch.observer/filing/0001104659-22-116477.txt

## Key facts
- Earnings Releases
  Rezolute, Inc. reported the first quarter of fiscal 2023 ended September 30, 2022 results: net income Net loss was $9.8 million for the first quarter of fiscal 2023.
  - Period: the first quarter of fiscal 2023 ended September 30, 2022
  - Net income: Net loss was $9.8 million for the first quarter of fiscal 2023
  - Result: reported results
  source text: Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to shift the treatment paradigms of devastating metabolic diseases, today announced its financial results for the first quarter of fiscal 2023 ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1509261/000110465922116477/0001104659-22-116477-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.